Healthcare / Elderly CareUS
← Sticker Wall
JOURNEY · DETAIL
Eli Lilly: Century-Old Pharma Giant Breaks into GLP-1 with Tirzepatide to Become a Trillion-Dollar Market Cap Titan
Founded: Eli Lilly · Eli Lilly and Company
JOURNEY
Key Fields
FIELD STAMPSIndustryHealthcare / Elderly Care
RegionUS
ScaleGiant
ChannelOther
Origin
Eli Lilly was founded in Indianapolis, USA in 1876 by pharmacist Eli Lilly. It initially started with standardized capsule technology and took the lead in commercializing animal insulin in 1923, laying a deep foundation in the diabetes field. In the late 20th century, Eli Lilly briefly focused on small-molecule and biologic drugs, but started relatively late on the new target of GLP-1 receptor agonists, being beaten to the punch by Novo Nordisk. Eli Lilly subsequently increased its investment, launched dulaglutide, and developed the more potent dual-target molecule tirzepatide. After 2022, it caught the wave of the weight-loss indication boom, achieving leapfrog growth.
Milestones
1876
Founded Growth
Pharmacist Eli Lilly founded Eli Lilly and Company in Indianapolis, USA in 1876, initially producing botanical extracts and capsules. In 1886, Eli Lilly hired chemist Ernst Schwartz to establish a research and development laboratory, shifting from selling packaged drugs to independent research and development, laying the foundation for standardized production by a century-old pharmaceutical company.
1923
Insulin Commercialization Growth
Eli Lilly partnered with the University of Toronto to take the lead in commercializing animal insulin under the product name Iletin, one of the world's first commercialized insulins. Leveraging its insulin products, Eli Lilly established a long-term advantage in diabetes treatment and continued to build its R&D capabilities for metabolic diseases over the following decades.
2016
Alzheimer's R&D Failure Failure
In November 2016, Eli Lilly announced that solanezumab, a heavily invested Alzheimer's disease candidate drug, failed to meet its primary endpoint in the Phase III clinical trial EXPEDITION3. The company's stock price plummeted by over 10% at one point, and billions of dollars in R&D investment went down the drain. This failure prompted Eli Lilly to internally re-examine its R&D pipeline, tilt resources toward diabetes and metabolic diseases, and pave the way for the subsequent high-priority development of tirzepatide.
2022
Tirzepatide Approved for Marketing Turning Point
In May 2022, the U.S. Food and Drug Administration (FDA) approved tirzepatide (brand name Mounjaro) for the treatment of type 2 diabetes. This new drug was the world's first dual-target medication simultaneously activating both GIP and GLP-1 receptors. In November 2023, the weight-loss indication version Zepbound was approved, allowing Eli Lilly to cut into the obesity market from the diabetes drug market, with prescription volume and sales rapidly climbing thereafter.
2026
$27.7 Billion in First-Half Sales Growth
According to Eli Lilly's financial reports, global sales of tirzepatide reached $27.7 billion in the first half of 2026, marking a significant year-on-year increase and driving continued growth in Eli Lilly's overall financial performance and market capitalization. The company also announced a $3 billion investment over the next decade to build oral weight-loss drug manufacturing capacity, and partnered with Chinese CDMO enterprises such as Asymchem for the first time to cope with global supply shortages.
Turning Points
- Following the failure of the Alzheimer's disease drug in 2016, Eli Lilly abandoned high-difficulty neurodegenerative disease R&D, concentrated its R&D resources on diabetes and metabolic fields, and turned tirzepatide from an original backup project into a strategic priority.
- After tirzepatide (Mounjaro) was approved for the type 2 diabetes indication in 2022, clinical data showed weight-loss effects far superior to competitors. Doctors and patients rapidly switched to tirzepatide, and prescription volumes ramped up faster than dulaglutide did during the same period.
- The approval of the Zepbound weight-loss indication in 2023 upgraded tirzepatide from a diabetes drug to a nationwide 'weight-loss injection.' Coupled with semaglutide's manufacturing capacity bottlenecks, Eli Lilly captured the largest incremental share in the U.S. market.
- In 2026, Eli Lilly announced an increased commitment to oral weight-loss drug capacity with a $3 billion investment over 10 years, attempting to build next-generation formulation barriers before patent expiration.
Failures & Pitfalls
- In 2016, the Phase III clinical trial of the Alzheimer's disease drug solanezumab failed, wiping out billions of dollars in investment, and Eli Lilly's R&D capabilities were temporarily questioned by Wall Street.
- In the early stages of the GLP-1 race, Eli Lilly's evaluation of delivery technology for oral peptide drugs was overly conservative, causing it to miss the first-mover advantage and allowing Novo Nordisk's semaglutide to capture the market years ahead.
- At the end of 2023, tirzepatide was listed by the U.S. FDA as a shortage drug due to exploding global demand and capacity bottlenecks. Some patients had to switch to competing products, and Eli Lilly temporarily relied on external contract manufacturing for injection pens to ease supply pressure.
关键成功要素
- Achieving superior clinical data through a dual-target mechanism; tirzepatide significantly outperformed semaglutide in weight-loss magnitude, which is the core reason doctors are willing to prescribe it.
- Developing multiple indications around the same molecule, expanding from type 2 diabetes to obesity, and further into sleep apnea, heart failure, etc. Each new indication corresponds to a tens-of-billions-dollar market.
- Treating manufacturing capacity as a second battlefield: Eli Lilly announced a $3 billion investment over the next decade in 2026 to build oral drug production capacity, and partnered for the first time with Chinese CDMOs like Asymchem, dramatically enhancing global supply capabilities.
- Proactively using next-generation products to self-iterate while patents have not yet expired, while betting on oral small-molecule GLP-1 drugs and dual-target/triple-target drugs to avoid falling off the patent cliff like other pharmaceutical companies.
Lessons
- The failure of costly blockbuster drug R&D does not equal the end; promptly adjusting pipelines and digesting lessons from failure are essential to nurturing the next blockbuster.
- The first mover in a popular race does not necessarily have the last laugh; latecomers can still achieve a comeback if their target design is more advantageous and clinical data is more robust.
- The commercial scaling of drugs is highly dependent on supply chains; successful R&D and factory commissioning must proceed simultaneously, otherwise the market may be handed over to competitors.
- A pharmaceutical company's market cap surge does not rely solely on a single drug, but rather on building an indication matrix and global manufacturing network around a target, forming systematic barriers.
Core Data
- H1 2026 Tirzepatide Sales：$27.7 billion (publicly available data basis, independent review not verified)
- Eli Lilly Market Cap：$1.0 trillion (publicly available data basis, independent review not verified)
- 2024 Full-Year Company Revenue：$45.043 billion (publicly available data basis, independent review not verified)
- 2023 Full-Year Company Revenue：$34.124 billion (publicly available data basis, independent review not verified)
- 10-Year Oral Weight-Loss Drug Capacity Investment：$3.0 billion (publicly available data basis, independent review not verified)
Competitors / Peers
Eli Lilly's primary rival is Novo Nordisk, which has long maintained its leadership position in GLP-1 through the semaglutide series (Ozempic, Wegovy), though it has been plagued by capacity and patent issues over the past two years. Pfizer's oral GLP-1 candidate drug danuglipron is also advancing; companies like Amgen and Boehringer Ingelheim are positioning themselves in weight-loss drugs to carve up this tens-of-billions-dollar market. Eli Lilly's core advantage lies in the stronger weight-loss data brought by tirzepatide's dual-target mechanism and its complete product pipeline ranging from injections to oral drugs, while also expanding indications into cardiovascular disease, heart failure, and sleep apnea, thereby covering a broader disease area than its competitors.
Sources
- https://m.36kr.com/p/3582051297360775
- https://www.zhengguannews.cn/zghnews/416617.html
- https://finance.sina.com.cn/jjxw/2026-07-24/doc-iniixnfz4801205.shtml
- https://www.huxiu.com/article/4881311.html
- https://finance.sina.com.cn/roll/2026-03-12/doc-inhqrvzf9110010.shtml
- https://www.36kr.com/p/3699787353124483